Pertussis - Pipeline Insight, 2024

This “Pertussis - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Pertussis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pertussis: Understanding

Pertussis: Overview

Pertussis, literally meaning “a violent cough,” and also known as whooping cough, or “the cough of 100 days,” was first described in the Paris epidemic of 1578. Bordetella pertussis, the causative organism, was discovered in 1906, and a vaccine was developed in the 1940s. Before the pertussis vaccine was developed, pertussis was a major cause of infant morbidity and mortality. Bordetella is a gram-negative coccobacillus that adheres to ciliated respiratory epithelial cells. Local inflammatory changes occur in the mucosal lining of the respiratory tract. Released toxins (pertussis toxin, dermonecrotic toxin, adenylate cyclase toxin, and tracheal cytotoxin) act locally and systemically, although the organism itself does not fully penetrate the respiratory tract, and almost never is found in blood cultures.

Pertussis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pertussis pipeline landscape is provided which includes the disease overview and Pertussis treatment guidelines. The assessment part of the report embraces, in depth Pertussis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence in Pertussis R&D. The therapies under development are focused on novel approaches to treat/improve in Pertussis.

• In January 2022, The Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1 for active booster immunization against pertussis.

This segment of the Pertussis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pertussis Emerging Drugs

DTwP-HepB-IPV-Hib: Serum Institute of IndiaA hexavalent conjugate vaccine (DTwP-HepB-IPV-Hib) is being developed by Serum Institute of India, for the prevention of diphtheria, tetanus, whole-cell pertussis (DTaP), poliomyelitis and Haemophilus influenzae type B (Hib) in infants.

BPZE 1: ILi AD Biotechnologies BPZE1 is an investigational live-attenuated intranasal vaccine designed to induce comprehensive and durable protection against Bordetella pertussis (B. pertussis) infection and disease. By blocking B. pertussis colonization in nasal passages, the vaccine may also prevent transmission, thereby reducing the incidence of pertussis disease. The designation is supported by data from 4 clinical trials evaluating BPZE1 inhealthyadults.

Pertussis: Therapeutic Assessment

This segment of the report provides insights about the different Pertussis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pertussis

There are approx. 15+ key companies which are developing the therapies for Pertussis. The companies which have their Pertussis drug candidates in the most advanced stage, i.e. Phase II/III include, Serum Institute of India

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pertussis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pertussis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pertussis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pertussis drugs.

Pertussis Report Insights

• Pertussis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pertussis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pertussis drugs?
• How many Pertussis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pertussis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pertussis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pertussis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Serum Institute of India
• LG Chem
• ILi ADBiotechnologies
• Dynavax Technologies
• Tianjin Can SinoBiotechnology
• Faron Pharmaceuticals
• Kymab
• BioNet

Key Products

• DTwP-HepB-IPV-Hib vaccine
• DTP-HepB-IPV-Hib vaccine
• BPZE 1
• Adjuvanted pertussis vaccine
• Diphtheria, tetanus and pertussis vaccine
• Bexmarilimab

Research programme: vaccines- Tetanus-reduced diphtheria-acellular pertussis vaccine

• SIIPL Tdap IPV

This product will be delivered within 2 business days.